{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:29:36Z","timestamp":1790908176833,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-05353-9","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:55:41Z","timestamp":1767106541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nationwide patterns of cardiac-related mortality in amyloidosis cases: an epidemiologic study"],"prefix":"10.1186","volume":"25","author":[{"given":"Abdalhakim","family":"Shubietah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Owda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Saad","family":"Rakab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Dawoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Khraiwesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-2875","authenticated-orcid":false,"given":"Mohamed S.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Tareq","family":"Mutar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Saad","family":"Al-Shammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer","family":"Awashra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"AbuBaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina","family":"Nazzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar","family":"Alyami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Daggubati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"1","key":"5353_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-Based treatment for Immunoglobulin Light-Chain amyloidosis. N Engl J Med. 2021;385(1):46\u201358.","journal-title":"N Engl J Med"},{"key":"5353_CR2","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020 July 7 [Cited 2025 Sept 20];142(1). Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/CIR.0000000000000792","DOI":"10.1161\/CIR.0000000000000792"},{"issue":"24","key":"5353_CR3","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"14","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;14(24):2404\u201312.","journal-title":"Circulation"},{"issue":"11","key":"5353_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"13","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;13(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"16","key":"5353_CR5","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1002\/sim.9407","volume":"20","author":"H Kim","year":"2022","unstructured":"Kim H, Chen H, Byrne J, Wheeler B, Feuer EJ. Twenty years since Joinpoint 1.0: Two major enhancements, their justification, and impact. Stat Med. 2022;20(16):3102\u201330.","journal-title":"Stat Med"},{"key":"5353_CR6","doi-asserted-by":"crossref","unstructured":"Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. Healthy People 2010 Stat Notes Cent. Dis Control Prev Cent Health Stat. 2001;(20):1\u201310.","DOI":"10.1037\/e583772012-001"},{"issue":"29","key":"5353_CR7","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","volume":"41","author":"PR Scully","year":"2020","unstructured":"Scully PR, Patel KP, Treibel TA, Thornton GD, Hughes RK, Chadalavada S, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41(29):2759\u201367.","journal-title":"Eur Heart J"},{"issue":"2","key":"5353_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","volume":"77","author":"C Nitsche","year":"2021","unstructured":"Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021;77(2):128\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"5353_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/jamasurg.2021.0528","volume":"156","author":"AA Ghaferi","year":"2021","unstructured":"Ghaferi AA, Schwartz TA, Pawlik TM. STROBE Reporting Guidelines for Observational Studies. JAMA Surg. 2021;156(6):577.","journal-title":"JAMA Surg"},{"issue":"22","key":"5353_CR10","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","volume":"75","author":"M Hanna","year":"2020","unstructured":"Hanna M, Ruberg FL, Maurer MS, Dispenzieri A, Dorbala S, Falk RH, et al. Cardiac scintigraphy with Technetium-99m-Labeled Bone-Seeking tracers for suspected amyloidosis. J Am Coll Cardiol. 2020;75(22):2851\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"5353_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plant\u00e9-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin Familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785\u201392.","journal-title":"Neurology"},{"key":"5353_CR12","doi-asserted-by":"publisher","first-page":"1108696","DOI":"10.3389\/fcvm.2023.1108696","volume":"10","author":"A Cersosimo","year":"2023","unstructured":"Cersosimo A, Bonelli A, Lombardi CM, Moreo A, Pagnesi M, Tomasoni D, et al. Multimodality imaging in the diagnostic management of concomitant aortic stenosis and transthyretin-related wild-type cardiac amyloidosis. Front Cardiovasc Med. 2023;10:1108696.","journal-title":"Front Cardiovasc Med"},{"key":"5353_CR13","unstructured":"U.S. FDA Approves VYNDAQEL\u00ae and VYNDAMAX\u2122 for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease | Pfizer . [Cited 2025 Oct 21]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_vyndaqel_and_vyndamax_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease"},{"issue":"9","key":"5353_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","volume":"151","author":"DP Judge","year":"2025","unstructured":"Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, et al. Long-Term efficacy and safety of acoramidis in ATTR-CM: initial report from the Open-Label extension of the ATTRibute-CM trial. Circulation. 2025;151(9):601\u201311.","journal-title":"Circulation"},{"issue":"1","key":"5353_CR15","first-page":"e68","volume":"32","author":"M Tanashat","year":"2025","unstructured":"Tanashat M, Bisht O, Abuelazm M, Altobaishat O, Khan U, Abouzid M. Transthyretin stabilizers treatment in patients with Transthyretin-Mediated cardiac amyloidosis: A systematic review and Meta-Analysis. Am J Ther. 2025;32(1):e68\u201378.","journal-title":"Am J Ther"},{"issue":"1","key":"5353_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33\u201344.","journal-title":"N Engl J Med"},{"issue":"17","key":"5353_CR17","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553\u201365.","journal-title":"N Engl J Med"},{"key":"5353_CR18","unstructured":"Amyloidosis SLC. Version 2.2023, NCCN Clinical Practice Guidelines in Oncology in: Journal of the National Comprehensive Cancer Network Volume 21 Issue 1 (2023) [Internet]. [Cited 2025 Oct 21]. Available from: https:\/\/jnccn.org\/configurable\/content\/journals$002fjnccn$002f21$002f1$002farticle-p67.xml?t:ac=journals%24002fjnccn%24002f21%24002f1%24002farticle-p67.xml"},{"issue":"7","key":"5353_CR19","doi-asserted-by":"publisher","first-page":"e70049","DOI":"10.1111\/eci.70049","volume":"55","author":"S Tabassum","year":"2025","unstructured":"Tabassum S, Naeem F, Rakab MS, Minhas AMK, Daggubati R, Alraies MC. Efficacy and safety of RNA interference therapeutics in transthyretin cardiac amyloidosis: A systematic review and meta-analysis. Eur J Clin Invest. 2025;55(7):e70049.","journal-title":"Eur J Clin Invest"},{"issue":"22","key":"5353_CR20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","volume":"322","author":"SM Damrauer","year":"2019","unstructured":"Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, et al. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry. JAMA. 2019;322(22):2191\u2013202.","journal-title":"JAMA"},{"issue":"6","key":"5353_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12170-021-00670-y","volume":"15","author":"G Spencer-Bonilla","year":"2021","unstructured":"Spencer-Bonilla G, Njoroge JN, Pearson K, Witteles RM, Aras MA, Alexander KM. Racial and ethnic disparities in transthyretin cardiac amyloidosis. Curr Cardiovasc Risk Rep. 2021;15(6):8.","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"4","key":"5353_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ahj.2009.08.006","volume":"158","author":"LH Connors","year":"2009","unstructured":"Connors LH, Prokaeva T, Lim A, Th\u00e9berge R, Falk RH, Doros G, et al. Cardiac amyloidosis in African americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and Immunoglobulin light chain amyloidosis. Am Heart J. 2009;158(4):607\u201314.","journal-title":"Am Heart J"},{"issue":"9","key":"5353_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","volume":"3","author":"KM Alexander","year":"2018","unstructured":"Alexander KM, Orav J, Singh A, Jacob SA, Menon A, Padera RF, et al. Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis. JAMA Cardiol. 2018;3(9):865.","journal-title":"JAMA Cardiol"},{"key":"5353_CR24","doi-asserted-by":"publisher","unstructured":"Shubietah A, Elgendy MS, Nazir A, Ahmed A, Awashra A, Taha HI, et al. Aortic dissection\u00a0mortality in the United States, 1968\u20132023: trends, disparities, and deep learning forecasts. Int J Cardiol Cardiovasc Risk Prev. 2025;100547. https:\/\/doi.org\/10.1016\/j.ijcrp.2025.200547.","DOI":"10.1016\/j.ijcrp.2025.200547"},{"issue":"1","key":"5353_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ahj.2009.05.013","volume":"158","author":"KT Bain","year":"2009","unstructured":"Bain KT, Maxwell TL, Strassels SA, Whellan DJ. Hospice use among patients with heart failure. Am Heart J. 2009;158(1):118\u201325.","journal-title":"Am Heart J"},{"key":"5353_CR26","unstructured":"Multiple Cause of. Death 1999\u20132020. [Cited 2025 Oct 21]. Available from: https:\/\/wonder.cdc.gov\/wonder\/help\/mcd.html"},{"issue":"1","key":"5353_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3121\/cmr.2019.1496","volume":"18","author":"LM Schuppener","year":"2020","unstructured":"Schuppener LM, Olson K, Brooks EG. Death certification: errors and interventions. Clin Med Res. 2020;18(1):21\u20136.","journal-title":"Clin Med Res"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05353-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05353-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05353-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:03:20Z","timestamp":1767150200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-025-05353-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5353"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05353-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study used publicly available, de\u2011identified data and was exempt from institutional review board approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"907"}}